These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12823593)

  • 1. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1.
    Formann E; Jessner W; Bennett L; Ferenci P
    J Viral Hepat; 2003 Jul; 10(4):271-6. PubMed ID: 12823593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.
    Lodato F; Azzaroli F; Brillanti S; Colecchia A; Tamé MR; Montagnani M; Muratori R; Giovanelli S; Feletti V; Bacchi Reggiani ML; Roda E; Mazzella G
    J Viral Hepat; 2005 Sep; 12(5):536-42. PubMed ID: 16108771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
    Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
    Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
    Manns MP; McHutchison JG; Gordon SC; Rustgi VK; Shiffman M; Reindollar R; Goodman ZD; Koury K; Ling M; Albrecht JK
    Lancet; 2001 Sep; 358(9286):958-65. PubMed ID: 11583749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial.
    Bosques-Padilla F; Trejo-Estrada R; Campollo-Rivas O; Cortez-Hernández C; Dehesa-Violante M; Maldonado-Garza H; Pérez-Gómez R; Cabrera-Valdespino A
    Ann Hepatol; 2003; 2(3):135-9. PubMed ID: 15115965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
    Perry CM; Jarvis B
    Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
    Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
    Perry CM; Jarvis B
    BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.
    Fülöp B; Biermer M; Cornberg M; Wedemeyer H; Port K; Heyne R; Zeuzem S; Peiffer KH; Welzel T; Herber A; Buggisch P; Moser C; Stoll S; Alshuth U; Berg T
    Liver Int; 2015 Oct; 35(10):2275-84. PubMed ID: 25801095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
    Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
    Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
    Nagaki M; Shimizu M; Sugihara JI; Tomita E; Sano C; Naiki T; Kimura K; Amano K; Sakai T; Ninomiya M; Kojima T; Katsumura N; Fujimoto M; Moriwaki H
    Aliment Pharmacol Ther; 2009 Aug; 30(4):343-51. PubMed ID: 19485982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.